LAUSR

Background: Characterization of Lung cancer treated with anti-PD1/PDL1 therapy was approach to predict the clinical benefit. This research is a prospective and observational study of long-term immunization therapy safety in routine clinical practice in lung cancer. Methods: This study obtained 395 Chinese patients lung cancer patients who underwent surgical resection or biopsies from January 2020 to January 2022. It is aimed to evaluated the value of TMB, MSI, and PD-1 expression in the pts subset that was therapy at anti-PD1/PDL1 therapy(n=47), other anticancer therapies (n=348) included chemoradiation therapy(55%), docetaxel(18%), EGFR-TKIs (16%), pemetrexed (5%) etc. Results: In this cohort, lung cancer pts treated with anti-PD1/PDL1 therapy had a higher proportion of MSI-H than others (7.7% vs 3.4%). PD-L1 High expression in two groups (anti-PD1/PDL1 therapy vs others) about in 19.1%(n=9) vs 10.6% (n=37), and low expression in 8.9% (n =31) vs 10.6% (n=5) pts. Median TMB was 13 mut/Mb from anti-PD1/PDL1 therapy and 9.6 mut/Mb from other therapy. Conclusions: Lung cancer pts were integrated after to immunotherapy vs other therapy, most pts received multiple subsequent anticancer therapies. In this study, immune-related biomarker analysis of lung cancer populations with multiple treatment methods may help improve the efficacy of precise treatment in lung cancer. Table Other therapy(n = 348) Anti-PD1/PDL1 therapy(n = 47) PD-L1 IHC High 10.6% 19.1% PD-L1 IHC Low 8.9% 10.6% TMB Median (mut/Mb) 9.6 13.0 MSS Status 76.0% 74.4% MSI Low Status 20.7% 17.9% MSI High Status 3.4% 7.7% Citation Format: Xin Zhao, Siyao Liu, Junyan Su. Clinical analysis of patients (pts) with lung cancer treated with anti-PD1/PDL1 therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 970.